Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia
| Autor: | Chunling Wang, Yue Chen, Banghe Ding, Yuan Deng, Lixiao Song, Zhengmei He, Shan-Dong Tao, Lanlan Ling, Liang Yu, Yuyue Shi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Acute promyelocytic leukemia Cancer Research Time Factors Retinoic acid Tretinoin Maintenance Chemotherapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Arsenic Trioxide Leukemia Promyelocytic Acute Recurrence immune system diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Term effect In patient Arsenic trioxide neoplasms Retrospective Studies business.industry organic chemicals All trans Treatment options Retrospective cohort study Hematology Prognosis medicine.disease Survival Analysis biological factors humanities Consolidation Chemotherapy Treatment Outcome Oncology chemistry 030220 oncology & carcinogenesis Retreatment Cancer research Female business 030215 immunology |
| Zdroj: | Leukemia & Lymphoma. 60:711-719 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2018.1504941 |
| Popis: | The specific prognostic factors and the long-term effects of different treatment options in APL remain unclear. In this retrospective study, 70 APL patients were treated with ATRA + DNR/DA or ATRA + ATO regimens for induction therapy and DA or ATRA + ATO for consolidation and maintenance therapy. The prognostic factors and treatment effects on outcome were analyzed. Results showed that the 5-year OS in low-intermediate risk and high risk groups were 95.63% and 100%, and the 5-year RFS were 95.34% and 100%, respectively, the early mortality rate was 4.28%. No significant difference was found on OS and RFS with different regimens, but side-effects and treatment-related mortality rates were lower in ATRA + ATO group. CD34 expression, FLT3-ITD mutation and PML-RARA isoform had no significance on OS and RFS. In conclusion, cytogenetic and molecular abnormalities had no influence on effect of APL patients; ATRA + ATO sequential maintenance may alleviate complications, treatment-related mortality, and the previously high risk factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|